DOP2009000167A - Vacuna - Google Patents

Vacuna

Info

Publication number
DOP2009000167A
DOP2009000167A DO2009000167A DO2009000167A DOP2009000167A DO P2009000167 A DOP2009000167 A DO P2009000167A DO 2009000167 A DO2009000167 A DO 2009000167A DO 2009000167 A DO2009000167 A DO 2009000167A DO P2009000167 A DOP2009000167 A DO P2009000167A
Authority
DO
Dominican Republic
Prior art keywords
protein
fusion proteins
antigen
vaccine
fusion
Prior art date
Application number
DO2009000167A
Other languages
English (en)
Inventor
Normand Blais
Remi M Palmantier
Denis Martin
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2009000167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of DOP2009000167A publication Critical patent/DOP2009000167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a proteínas de fusión que comprenden un antígeno derivado del llamado antígeno de rechazo de tumor PRAME (también conocido como DAGE) enlazado a un participe de fusión inmunológica que proporciona epítopes auxiliares-T, tales como por ejemplo, proteína D de Haemophilus influenzae B, proteínas participe de fusión que comprenden los fragmentos de la proteína D, métodos para preparar los mismos y la formulación de vacunas y uso de los mismos para tratar un rango de cánceres.
DO2009000167A 2007-01-15 2009-07-02 Vacuna DOP2009000167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine

Publications (1)

Publication Number Publication Date
DOP2009000167A true DOP2009000167A (es) 2009-07-15

Family

ID=39300029

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000167A DOP2009000167A (es) 2007-01-15 2009-07-02 Vacuna

Country Status (32)

Country Link
US (1) US20080187535A1 (es)
EP (1) EP2114993B1 (es)
JP (1) JP5391080B2 (es)
KR (1) KR20090101313A (es)
CN (1) CN101668770B (es)
AR (1) AR064862A1 (es)
AU (1) AU2008207025B2 (es)
BR (1) BRPI0806463A2 (es)
CA (1) CA2674552A1 (es)
CL (1) CL2008000104A1 (es)
CO (1) CO6210757A2 (es)
CR (1) CR10971A (es)
CY (1) CY1113760T1 (es)
DK (1) DK2114993T3 (es)
DO (1) DOP2009000167A (es)
EA (1) EA016326B1 (es)
ES (1) ES2393812T3 (es)
HK (1) HK1138853A1 (es)
HR (1) HRP20120828T1 (es)
IL (1) IL199663A0 (es)
JO (1) JO2840B1 (es)
MA (1) MA31093B1 (es)
MX (1) MX2009007571A (es)
MY (1) MY153679A (es)
NZ (1) NZ578285A (es)
PE (2) PE20081686A1 (es)
PL (1) PL2114993T3 (es)
PT (1) PT2114993E (es)
SI (1) SI2114993T1 (es)
TW (1) TWI434697B (es)
WO (1) WO2008087102A1 (es)
ZA (1) ZA200904923B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081687A1 (es) * 2007-01-15 2008-12-25 Glaxosmithkline Biolog Sa Proteina de fusion
WO2010105815A2 (en) 2009-03-17 2010-09-23 Oncomethylome Sciences S.A. Improved detection of gene expression
WO2010141953A2 (en) * 2009-06-05 2010-12-09 The Ohio State University Research Foundation Biomaterials, compositions, and methods
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
KR20140049569A (ko) * 2011-07-22 2014-04-25 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｐｒａｍｅ 정제
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
CA2925658C (en) 2013-10-01 2022-12-06 Mie University Long chain antigen containing interepitope sequence that promotes antigen presentation to t cells
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
JP2021502083A (ja) * 2017-11-08 2021-01-28 アドバクシス， インコーポレイテッド がん関連タンパク質由来の免疫原性ヘテロクリティックペプチドおよびその使用の方法
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CN1120809A (zh) * 1993-12-23 1996-04-17 Gff工业方向促进研究公司 增强免疫应答的方法
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
PT1659178E (pt) * 1998-02-05 2010-06-28 Glaxosmithkline Biolog Sa Processo para a purificação ou produção de uma proteína mage
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
JP2003504074A (ja) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導

Also Published As

Publication number Publication date
ES2393812T3 (es) 2012-12-28
AU2008207025A1 (en) 2008-07-24
MA31093B1 (fr) 2010-01-04
IL199663A0 (en) 2010-04-15
KR20090101313A (ko) 2009-09-24
CN101668770A (zh) 2010-03-10
AR064862A1 (es) 2009-04-29
PE20081686A1 (es) 2008-12-25
HRP20120828T1 (hr) 2012-11-30
TW200902048A (en) 2009-01-16
AU2008207025B2 (en) 2012-08-23
CO6210757A2 (es) 2010-10-20
MX2009007571A (es) 2009-07-22
CN101668770B (zh) 2013-06-12
PE20130324A1 (es) 2013-03-05
CL2008000104A1 (es) 2008-07-18
WO2008087102A1 (en) 2008-07-24
EP2114993B1 (en) 2012-08-29
TWI434697B (zh) 2014-04-21
MY153679A (en) 2015-03-13
BRPI0806463A2 (pt) 2011-09-06
HK1138853A1 (en) 2010-09-03
PT2114993E (pt) 2012-11-28
NZ578285A (en) 2011-12-22
JP5391080B2 (ja) 2014-01-15
CA2674552A1 (en) 2008-07-24
JP2010515444A (ja) 2010-05-13
CR10971A (es) 2009-09-09
PL2114993T3 (pl) 2013-01-31
EA200900795A1 (ru) 2010-02-26
ZA200904923B (en) 2012-12-27
EA016326B1 (ru) 2012-04-30
DK2114993T3 (da) 2012-10-22
US20080187535A1 (en) 2008-08-07
EP2114993A1 (en) 2009-11-11
JO2840B1 (en) 2014-09-15
SI2114993T1 (sl) 2012-12-31
CY1113760T1 (el) 2016-07-27

Similar Documents

Publication Publication Date Title
DOP2009000167A (es) Vacuna
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
NZ743881A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
BR112017019785A2 (pt) anticorpos terapêuticos e seus usos
CR20200595A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
EA201891638A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
BR112018009980A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres
EA201992664A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
BR112017028363A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
MX2020011791A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
NZ765527A (en) Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
AR111000A1 (es) Moléculas de unión biespecíficas que son capaces de unirse a cd137 y a antígenos tumorales, y usos de las mismas
EA202190241A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
EA202190465A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
TH126648A (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น
AR064925A2 (es) Proceso para la purificacion de una proteina mage para preparar una vacuna, dicha vacuna y su uso para la fabricacion de un medicamento
TH126648B (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น